Drug Profile
GSK 2302024A
Alternative Names: GSK2302024A; WT1-A10+AS15 ASCILatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 01 Aug 2014 GlaxoSmithKline terminates phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) in Belgium, France, Germany, Italy, Russia, the US and the UK (NCT01220128)
- 31 Jul 2013 Phase II clinical trials in Breast cancer (neoadjuvant, in combination with standard therapy) in Belgium, Russia and USA prior to July 2013 (IM) (NCT01220128)
- 01 Apr 2011 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy) in Germany (IM)